The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids

European Journal of Clinical Pharmacology

Volumn 53, Issue 5, 1998, Pages 351-354

  Lukkari, E ^a,b   Hakonen, T ^b   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Oy Leiras Finland Ab   (Finland)

Author keywords

Contraceptive steroids; Oxybutynin

Indexed keywords

CONTRACEPTIVE AGENT; OXYBUTYNIN; PLACEBO;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG METABOLISM; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS; DEMOGRAPHIC FACTORS; DEVELOPED COUNTRIES; EUROPE; FAMILY PLANNING; FINLAND; HUMAN VOLUNTEERS; NORTHERN EUROPE; POPULATION; POPULATION CHARACTERISTICS; RESEARCH METHODOLOGY; RESEARCH REPORT; SCANDINAVIA; SEX FACTORS;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHOLINERGIC ANTAGONISTS; CONTRACEPTIVES, ORAL, HORMONAL; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MANDELIC ACIDS; SEX FACTORS;

EID: 0031890687     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050392     Document Type: Article

References (12)

1. Aaltonen L, Allonen H, Iisalo E, Juhakoski A, Kleimola T, Sellman R (1984) Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay. Acta Pharmacol Toxicol 55: 100-103
2. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35: 515-520
3. Hughes KM, Lang JC, Lazare R, Gordon D, Stanton SL, Malone-Lee J, Gerant M (1992) Measurement of oxybutynin and its N-Desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly subjects. Xenobiotica 22: 859-869
4. Yaich M, Popon M, Jacqz Aigrain E (1995) The metabolism of oxybutynin is dependent on CYP3A and not on CYP2D6 (abstract). Therapie 50 [Suppl]: 67
5. Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50: 222-239
6. Gleiter CH, Gundert-Remy U (1996) Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 21: 123-128
7. Back DJ, Orme ML'E (1990) Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18: 472-484
8. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3: 363-371
9. Back DJ, Houlgrave R, Tjia JF, Ward S, Orme ML'E (1991) Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol 38: 219-225
10. Chambers DM, Jefferson GC (1982) Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids. Br J Clin Pharmacol 13: 229-232
11. Jung-Hoffman C, Kuhl H (1989) Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 40: 299-312
12. Field B, Cherry L, Hepner GW (1979) Inhibition of hepatic drug metabolism by norethindrone. Clin Pharmacol Ther 25: 196-198